Abstract
Glucose-6-phosphate dehydrogenase (G6PD) play an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), and it can be regarded as one of the targets in their treatment. However, the data on changes in the G6PD activity in these diseases are scarce. The aim of this work was to study the G6PD activity in the brain, myocardium and epididymal fat (EF) in male rats with T2DM and MS and the influence of long-term treatment with antidiabetic drug metformin (MF) on it. To induce T2DM, five-day rat pups were treated with streptozotocin (75 mg/kg). The MS in rats was induced by diet consisting of 30% glucose solution and saturated fats. The treatment of T2DM and MS was carried out at a daily dose 200 mg/kg for 5 or 10 weeks. It was shown that in the brain of rats with T2DM and MS the G6PD activity changed weakly. In the myocardium and EF in rats with T2DM and MS the G6PD activity significantly increased. The treatment of animals with MF led to decrease of this activity, and in the myocardium of rats with T2DM the enzyme activity reached its level in control. Thus, we showed that in the myocardium and EF of rats with T2DM and MS the G6PD activity was significantly increased, and the MF treatment normalized it, which is one of the mechanisms of therapeutic action of MF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
